CellaVision and Sysmex announce a jointly-developed product for hematology labs
(Thomson Reuters ONE) -
This information was released for public disclosure on April 16, 2013 at 3.00 pm
CET.
CellaVision today announced that the company and its partner Sysmex have co-
developed a product which integrates CellaVision Digital Cell Morphology
technology with the Sysmex XN-series hematology platform. The product, DI-60,
will be part of the global Sysmex product portfolio for hematology laboratories.
For the first time, digital cell morphology has been successfully integrated
with a cell counter and slide preparation device, eliminating the need to
manually load the slide for analysis, thus further streamlining the hematology
workflow and providing highest testing efficiency.
Since 2001, CellaVision has had a successful distribution arrangement with
Sysmex and together both parties created the market for digital microscopy
analysis. With this joint product development, Sysmex and CellaVision have
demonstrated a new level of excellence in cooperation.
The target market is primarily clinical laboratories with medium to large sample
volumes. With the DI-60 product Sysmex enhances their product portfolio of
digital cell morphology products, including the CellaVision DM96 and DM1200
systems. Similar to CellaVision's other products the DI-60 automates work
traditionally performed manually under a microscope. Test results are stored
digitally with images of blood cells and other patient information, increasing
the efficiency while improving the quality of the manual differential.
Sysmex plans to present the DI-60 for the first time at the trade fair IFCC
EUROMEDLAB 2013 in Milan, Italy, on May 19-23, 2013.
For more information please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708-33 77 82 | Email: yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. In most countries sales are
via global partners. The products are sold directly in the Nordic countries and
via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million
and sales continue to increase, with a growth target of at least 15 % per year
over an economic cycle. CellaVision's registered office is in Lund, Sweden. The
share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
About Sysmex Corporation
www.sysmex.com
Publication
This information is disclosed by CellaVision AB (publ) pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public disclosure on April 16, 2013 at 3.00 pm CET.
Press release as PDF:
http://hugin.info/132164/R/1693018/556389.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1693018]
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2013 - 15:00 Uhr
Sprache: Deutsch
News-ID 249526
Anzahl Zeichen: 3940
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 153 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision and Sysmex announce a jointly-developed product for hematology labs"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
